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Pulmonary arterial hypertension (PAH) is a rare disorder that may be hereditable (HPAH), idiopathic (IPAH), or associ-
ated with either drug-toxin exposures or other medical conditions. Familial cases have long been recognized and are
usually due to mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2), or, much less commonly,
2 other members of the transforming growth factor- superfamily, activin-like kinase-type 1 (ALK1) and endoglin
(ENG), which are associated with hereditary hemorrhagic telangiectasia. In addition, approximately 20% of patients
with IPAH carry mutations in BMPR2. We provide a summary of BMPR2 mutations associated with HPAH, most of
which are unique to each family and are presumed to result in loss of function. We review the finding of missense
variants and variants of unknown significance in BMPR2 in IPAH/HPAH, fenfluramine exposure, and PAH associated
with congenital heart disease. Clinical testing for BMPR2 mutations is available and may be offered to HPAH and
IPAH patients but should be preceded by genetic counseling, since lifetime penetrance is only 10% to 20%, and there
are currently no known effective preventative measures. Identification of a familial mutation can be valuable in repro-
ductive planning and identifying family members who are not mutation carriers and thus will not require lifelong sur-
veillance. With advances in genomic technology and with international collaborative efforts, genome-wide association
studies will be conducted to identify additional genes for HPAH, genetic modifiers for BMPR2 penetrance and genetic
susceptibility to IPAH. In addition, collaborative studies of BMPR2 mutation carriers should enable identification of
environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy
end points in clinical drug development, thereby providing an invaluable resource for trials of PAH prevention. (J Am
Coll Cardiol 2009;54:S32–42) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.015i
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aulmonary arterial hypertension (PAH) is a rare disorder
ith an estimated incidence of approximately 2 cases per
illion per year (1,2). It is characterized by a sustained
rom *Department of Medical and Molecular Genetics, King’s College London
chool of Medicine, Guy’s Hospital, London, United Kingdom; †Comprehensive
neumology Center, Ludwig-Maximilians-Universität, Asklepios Klinik Gauting
nd Helmholtz Zentrum München, and Institute of Lung Biology and Disease
iLBD), Helmholtz Zentrum München, Munich, Germany; ‡Departments of Med-
cine, Intermountain Medical Center and the University of Utah School of Medicine,
alt Lake City, Utah; §Division of Pulmonary Sciences and Critical Care Medicine,
niversity of Colorado Health Sciences Center, Denver, Colorado; First Depart-
ent of Medicine, Shinshu University School of Medicine, Matsumoto, Japan;
Department of Medicine, and #Department of Pediatrics and Division of Medical
enetics, Vanderbilt University School of Medicine, Nashville, Tennessee; **Faculté
e Medicine, Université Paris 6, Hôpital Pitié-Salpêtrière, Paris, France; and the
†Departments of Pediatrics and Medicine, Columbia University College of Physi-
ians & Surgeons, New York, New York. Funding provided by NHLBI 060056,
eseret Foundation, Intermountain Medical Center, NIH PO1 HL072058, GCRC
R000095, German Research Foundation (DFG) Collaborative Research Center 547
to Dr. Eickelberg), the Excellence cluster “Cardiopulmonary System” (ECCPS),
uropean Commission under the 6th Framework Programme (contract no.: LSHM-
T-2005-018725, PULMOTENSION), and BHF-FS/07/036. Please see the end ofe
his article for each author’s conflict of interest information.
Manuscript received February 6, 2009, accepted April 15, 2009.ncrease in mean pulmonary artery pressure (25 mm Hg at
est or 30 mm Hg with exercise), normal pulmonary
apillary wedge pressure, and increased pulmonary vascular
esistance. For adults, mean age at presentation ranges from
6 to 50 years, although individuals of any age can be
ffected (2,3). Prior to the advent of modern therapies, life
xpectancy for adults with idiopathic pulmonary arterial
ypertension (IPAH) was 3 years from diagnosis; for
hildren, it was 10 months (4).
Pulmonary arterial hypertension may be heritable (HPAH),
diopathic, or associated with drug or toxin exposures (fenflu-
amine derivatives or toxic oil syndrome), or other medical
onditions, including connective tissue diseases, human immu-
odeficiency virus infection, congenital heart disease, and
ortal hypertension. Familial cases have long been recognized
5), and in 2000, bone morphogenetic protein receptor type 2
BMPR2) was identified following linkage analysis (6–8) as
he gene responsible for more than 70% of HPAH and
pproximately 20% of IPAH cases (9–12). Crude indirect
stimates of the population carrier frequency for BMPR2
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June 30, 2009:S32–42 Genetics and Genomics of PAHutations lie in the frequency range of 0.001% to 0.01% (13).
wo further receptor members of the transforming growth
actor (TGF)- cell signaling superfamily are also recognized
s uncommon causes of HPAH. Heterozygous mutations in
ctivin-like kinase-type 1 (ALK1) (14) and endoglin (ENG)
15) cause hereditary hemorrhagic telangiectasia (HHT) and
ay rarely lead directly to the development of PAH.
Heritable PAH is inherited as an autosomal dominant
rait with incomplete penetrance and an estimated lifetime
isk of 10% to 20% (16). The disease is more frequent in
omen, with a ratio of at least 1.7:1 women to men
2,17,18). Both incomplete penetrance and the significantly
kewed gender ratio suggest interactions between BMPR2
isease mutations and environmental exposures that may
nclude hormones, together with a role for modifying genes.
he latest classification scheme now replaces the term
amilial PAH with HPAH, at least in part to recognize the
act that up to 20% of cases previously thought to be IPAH
arbor identifiable mutations in BMPR2 and therefore pose
hereditary risk to other family members. Only 6% of PAH
atients reported a family history of PAH in the prospective
ational Institutes of Health registry (18). A family history
f PAH may go unrecognized in IPAH cases with BMPR2
utations, as a consequence of either incomplete penetrance
r de novo (spontaneous) mutations. Heterozygous BMPR2
equence variants have been identified in a small subset of
atients with PAH associated with relatively brief exposure
o fenfluramine (13,19) or with congenital heart disease
20), raising the question as to whether such factors repre-
ent disease triggers in the face of inherited susceptibility in
ome patients. In contrast, BMPR2 mutations have not
een identified in PAH associated with the scleroderma-
pectrum of disease or with human immunodeficiency virus
21,22).
HPAH and IPAH have a similar clinical course. HPAH
s associated with a slightly younger age of onset and a
lightly more severe hemodynamic impairment at diagnosis,
ut with similar survival (23). Patients with PAH and
isease-causing BMPR2 mutations are, however, less likely
o respond to acute vasodilator testing during right heart
atheterization and are unlikely to benefit from treatment
ith calcium channel blockade (23–25).
enetic Anticipation
amilies with BMPR2 mutations have been reported to
ave genetic anticipation, or earlier age of diagnosis in
ubsequent generations (17). However, no systematic
opulation-based study has been performed to avoid the
scertainment bias that could result in the recruitment and
tudy of families associated with earlier-onset disease in
ore recent generations. Furthermore, the usual genetic
echanisms for anticipation, including trinucleotide repeat
xpansions, are not present in BMPR2. The question of
enetic anticipation can be better addressed in future reg-
stries in which all patients with HPAH and IPAH can be cenetically characterized and un-
iased family studies can be per-
ormed.
he TGF- Family and PAH
he TGF- superfamily com-
rises a large series of cytokine
rowth factors that control a host
f cellular functions, among them
roliferation, migration, differen-
iation, apoptosis, and extracellular
atrix secretion and deposition.
isplaying high evolutionary con-
ervation across species, TGF-
embers are segregated into sev-
ral subfamilies, notably the proto-
ypic TGF- ligands, receptors,
nd accessory molecules, activins,
nd the largest of these groups, the
one morphogenetic proteins (26).
he implication of BMPR2,
LK-1, and ENG as causal factors
n hereditary and associated forms
f PAH has emphasized the criti-
al importance of this pathway to the integrity of the pulmo-
ary vasculature (27).
MPR-II Structure and Signal Transduction
he 4 functional domains of TGF- type II receptors are
ypically highly conserved across the family. They consist of
n N-terminal ligand binding domain, a single transmem-
rane region, a serine/threonine kinase, and a cytoplasmic
ail domain. Particular to BMPR-II, however, is the
resence of an exceptionally long postkinase cytoplasmic
omain, primarily encoded by exon 12 of the gene. A
econd isoform, generated by alternative splicing of exon
2, is expressed ubiquitously at the mRNA level, al-
hough the in vivo function of the mature polypeptide
emains enigmatic (28).
Signal transduction routed through the TGF- pathway
as been extensively interrogated over the last 2 decades; in
ontrast, BMP signaling remains less well described. The
aradigmatic BMP pathway is a phosphorylation relay of
ignaling intermediaries initiated at the cell surface and
ulminating in the nucleus (Fig. 1) (29). A heterotetrameric
omplex consisting of type I receptors, for example ALK1,
MPR1A or BMPR1B, and BMPR-II, amalgamate to
ind extracellular dimeric ligand. These interactions pro-
ote close receptor species proximity and activation of the
ype I receptor by the constitutive kinase BMPR-II. The
ype I receptors, in turn, bind and phosphorylate members
f the receptor R Smad family, namely SMAD1/5 or 8.
hen activated, the affinity of the R-Smads for a nuclear
Abbreviations
and Acronyms
ALK1  activin-like kinase
type 1
BMPR2  bone
morphogenetic protein
receptor type 2
ENG  endoglin
GRR  genotypic relative
risk
GWA  genome-wide
association
HHT  hereditary
hemorrhagic telangiectasia
HPAH  heritable
pulmonary arterial
hypertension
IPAH  idiopathic
pulmonary arterial
hypertension
PAH  pulmonary arterial
hypertension
TGF  transforming growth
factorhaperone, Smad-4, common across the TGF- system, is
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Genetics and Genomics of PAH June 30, 2009:S32–42ugmented. These complex-bound signaling molecules
huttle to the nucleus, where, in concert with specific
uclear cofactors and repressors, they influence regulation of
limited set of target genes (26). Within the framework of
n essentially uncomplicated canonical pathway, the speci-
city and flexibility of signaling outcomes are tightly main-
ained by the myriad, cell-specific levels of regulation
xtending from sequestration of extracellular ligand to
nhibitive competition of type I receptors by nonfunctional
ecoy receptors and extensive cross-talk with other signaling
athways including p38MAPK, the cytoskeleton-associated
roteins Tctex-1 and LIMK-1 (26,30–32), and c-src and
ACK-1 (33,34).
The burgeoning understanding of TGF- receptor struc-
ure and function has been an invaluable aid in determining
he likely impact of BMPR2 mutations in PAH. Con-
ersely, and of equivalent importance, analysis of the spec-
rum and pattern of these defects, in conjunction with
irected functional studies, has confirmed and better re-
olved those regions of the receptor necessary for normal
hysiologic activity.
ajor Genetic Risk Factors in PAH
hrough the compilation of previously reported mutation
Figure 1 BMPR2 Signal Transduction
Upon binding ligand, the type II receptor phosphorylates a type I partner, which ma
propagation of cytoplasmic signal transduction through the R-Smads 1/5/8, or, in
to the nucleus and, in complex with transcriptional cofactors, modulate the expresata, combined with an ongoing global collaboration tar- beted at conducting systematic and comprehensive screen-
ng of patient samples, a combined total of 298 BMPR2
utations have been identified (35). Of these, 88 are novel
Table 1) (36–39). These mutations were identified in
ndependent probands, including those with a known PAH
amily history, sporadic onset of disease, and PAH associ-
ted with other disorders. All mutations studied to date
ppear to have risen on unrelated genetic backgrounds,
uggesting that genetic founder events are uncommon (35).
ndeed, approximately 41% (122 of 298) of all recorded
MPR2 mutations are small deletions or insertions at sites
f low-complexity sequence or as a consequence of CT
ransitions, presumably resulting from the relatively com-
on process of spontaneous cytosine deamination. Thus,
espite the fact that PAH typically presents as a late-onset
isease, ancestral mutations in this gene are at best rare,
ossibly because of a deleterious effect on reproductive
tness. In addition, we describe uncommon genetic suscep-
ibilities, including ALK-1 defects in PAH and PAH
ssociated with HHT.
utation in BMPR2 Constitutes
he Primary Genetic Risk in PAH
wide range of mutation detection methodologies have
MPR1A/B or upon activation by the ligands BMP9/10, ALK-1. This leads to a
dently, via the p38MAPKs. In association with Smad4, the R-Smads translocate
f a target set of genes.y be B
depen
sion oeen employed to screen patients for point mutations and
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June 30, 2009:S32–42 Genetics and Genomics of PAHarge gene rearrangements, among them direct sequencing,
elting curve analysis, denaturing high-performance liquid
hromatography, Southern blotting, and multiplex ligation-
ependent probe amplification. To date, mutations have
een recorded in over 70% of subjects with 1 or more
ffected relatives, whereas in idiopathic cases, mutation
etection rates between centers range from 10% to 40%
12,19,36,40). Of interest, mutations of TGF- superfamily
embers have also been observed in associated forms of
AH, albeit at far lower frequencies (35). The spectrum of
MPR2 mutations in hereditary and spontaneous disease is
nalogous, comprising all major classes of mutations. Mu-
ations predicting premature truncation of the polypeptide
hain are the most prevalent (203 of 298, 68%). Although
here is another putative PAH locus at 2q32 that was
apped in part by using stress echocardiography to detect
symptomatic obligate carriers (41), no gene has yet been
dentified from this interval. Thus, to date, mutations in
MPR2 remain the primary genetic susceptibility for PAH.
runcating Mutations of
MPR2 in Heritable and Idiopathic PAH
utations predicted to introduce premature truncation
odons to the BMPR2 open reading frame encompass
onsense (85 of 298, 29%), frame-shift (73 of 298, 24%),
plice-site (26 of 298, 9%), and gene duplications/deletions
19 of 298, 6%). An exception of note is a double substitu-
ion of 2 consecutive bases (GCAT) identified in a large
AH kindred 944 base pairs upstream of the translation
tart site (36). Bioinformatic assessment indicated that the
utation, within the context of flanking sequence, would
ikely generate the formation of an aberrant translational
tart signal, consequently leading to incorporation of a
remature stop codon in the first exon of the gene. Allele-
pecific polymerase chain reaction assays utilizing variant
nd cell-based studies to examine activation of the
onsense-mediated decay (NMD) surveillance machinery
ave confirmed both degradation and loss of the mutant-
arboring transcript. Indeed, both conventional studies on
atient cell lines and novel in vitro technologies demon-
trate that the majority of mutations in this class are rapidly
emoved from the cell via the NMD pathway (36,42).
long with the observation of large proximal and whole
eletions of BMPR2, these findings now firmly substantiate
aploinsufficiency as the predominant molecular mechanism
nderlying BMPR2 predisposition to hereditary and idio-
athic forms of disease (11,13,43).
istribution and Impact of Missense Mutations
cross Conserved Functional Domains of BMPR2
issense mutations of BMPR2 in HPAH/IPAH cluster
ainly in regions of the gene-encoding receptor domains
ndispensable to signaling activity and are confined to exons
, 3, 6 to 9, 11, and 12. The extracellular ligand-binding
omain of BMPR-II adopts a precisely folded conforma- dion, exquisitely dependent on the formation of 5 disul-
hide bridges by 10 cysteine residues dispersed across
xons 2 and 3, invariant in the majority of type II
eceptors (44). Amino acid substitutions in this domain
re common, particularly at the cysteine residues, with 17
f 22 independent cysteine mutations affecting 8 of the
0 conserved residues. Subcellular analysis of all tested
ysteine mutant constructs demonstrates substantial cy-
osolic retention, likely to be due to a profound loss of
onformational integrity (45,46).
The BMPR-II catalytic domain shares the fundamen-
al structural and functional characteristics of members of
he extensive eukaryotic protein kinase superfamily. The
inase region is compartmentalized into 12 subdomains
f variable importance to the processes of adenosine
riphosphate binding, substrate recognition, and phosphate
roup transfer (47). However, dispersed across the subdo-
ains are 12 critical, highly conserved, amino acid residues.
issense mutations are typically restricted to regions crucial
o kinase activity, as best exemplified by substitution of the
ative arginine residue at the invariant position 491, a site of
requent and recurrent mutation in PAH. Disruption of the
ey structural interaction between this residue and a glu-
amic acid at position 386 effectively renders the receptor
inase inactive. Whereas noncysteine substitutions traffic
ormally to the cell surface, all kinase mutations occurring
n these catalytically important domains display a near
omplete abolition of signaling through the Smad pathway
45,46).
ariants of Unknown Significance in PAH
mino acid substitutions are seldom observed in the cyto-
lasmic domain of BMPR-II (7 of 298, 2%), in contrast to
runcating mutations, which account for approximately 15%
f the overall mutation load in PAH. Furthermore, mis-
ense mutations in this region are functionally distinct from
lassical PAH-causing defects, as they are associated with
ormal levels of Smad activation (45,46). Instead, in tran-
ient transfection-based assays, disease-specific substitutions
f the cytoplasmic tail appear to constitutively activate
38MAPK and impede phosphorylation of the dynein light
hain Tctex-1 (32,46). Thus, this domain of the receptor is
ignificant in relaying receptor signal through Smad-
ndependent pathways. The relevance of this finding to
isease pathogenesis is currently under investigation.
The mutation spectrum in PAH associated with other
onditions or acknowledged risk factors, for example, fen-
uramine use, is distinct from the mutation spectrum in
ereditary/idiopathic disease (35). PAH patients with fen-
uramine exposure exclusively harbor missense mutations,
n comparison to only one-third of patients with HPAH.
oreover, the substitutions occur at positions not recog-
ized as having a major impact on receptor function. For
xample, none of the 5 reported variants in the extracellular
omain observed in patients with PAH and congenital heart
PS36 Machado et al. JACC Vol. 54, No. 1, Suppl S, 2009
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Table 1 Pathogenic BMPR2 Mutations in PAH
Location
Mutation
Category Domain Nucleotide Change Amino Acid Change
Frequency in
This Study Comment Reference
5= UTR Missense c.*-944/5GCAT 1 H Aldred et al. (36)
5= UTR and Exon 1 Deletion c.?_-540_76?del 1 H This analysis
Exon 1 Missense c.28CT p.T10W 1 I Baloira et al. (37)
Nonsense c.71CA p.A24E 1 I This analysis
Intron 1 Splice-site c.765GA 1 I This analysis
Exon 2 Nonsense ECD c.124CT p.Q42X 1 I Fujiwara et al. (38)
Frameshift ECD c.186insTACC p.G63fsX1 1 H This analysis
Frameshift ECD c.189_207delins14 p.S64EfsX32 1 ASD/PAH This analysis
Deletion ECD c.189-209del21 p.del6470(STCYGLW) 1 H This analysis
Nonsense ECD c.201TG p.Y67X 1 H This analysis
Missense ECD c.247GA p.G83R 1 I This analysis
Exons 1–4 Deletion ECD c.1-?_419?del 1 I This analysis
Exons 1–8 Deletion ECD c.1-?_1128?del 1 I This analysis
Intron 2 Splice-site ECD c.2471delCAAGTG 1 H This analysis
Splice-site ECD c.2471_4 delGTAA p.C84_S140del 1 I This analysis
Splice-site ECD c.248-2AG 1 H This analysis
Splice-site ECD c. 248-5 delTATAGGinsAC 1 H This analysis
Exon 3 Missense ECD c.248GA p.G83E 1 H This analysis
Missense ECD c.250TC p.C84R 1 H This analysis
Missense ECD c.250TG p.C84G 1 I This analysis
Frameshift ECD c.261insA p.87fsX9 1 H This analysis
Missense ECD c.295TC p.C99R 1 H This analysis
Missense ECD c.296GT p.C99F 1 I This analysis
Missense ECD c.296GA p.C99Y 1 H This analysis
Nonsense ECD c.339CA p.Y113X 1 I This analysis
Nonsense ECD c.339CG p.Y113X 1 I Fujiwara et al. (38)
Missense ECD c.350GA p.C117Y 1 H This analysis
Nonsense ECD c.354-355TAAG p.C118X 1 H This analysis
Missense ECD c.367TC p.C123R 1 I Fujiwara et al. (38)
Missense ECD c.370AG p.N124D 1 I This analysis
Missense ECD c.377AG p.N126S 1 I This analysis
Deletion ECD c.248-?_418?del 2 H,H This analysis
Exon 2–3 Deletion ECD c.77-?_418?del 5 H,H,H,H,I This analysis
Intron 3 Splice-site ECD c.4181GC 1 H This analysis
Splice-site ECD c.4185GA 2 H This analysis
Exons 4–5 Deletion ECD c.419-?_621?del 2 H,I This analysis
Exon 5 Nonsense TM c.583GT p.E195X 1 PVOD This analysis
Missense TM c.604AT p.N202Y 1 PVOD This analysis
Exon 6 Frameshift KD c.612delA p.L204fsX5 1 H This analysis
Nonsense KD c.631CT p.R211X 2 H This analysis
Frameshift KD c.660insG p.G220fsX4 1 NK This analysis
Frameshift KD c.690-691delAGinsT p.K239fsX21 1 H This analysis
Missense KD c.794AG p.E265G 1 I This analysis
Missense KD c.797GC p.R266T 1 NK This analysis
Missense KD c.806GT p.A268V 1 I Baloira et al. (37)
Intron 6 Splice-site KD c.8521GC 1 I This analysis
Splice-site KD c.853-1GC 1 H This analysis
Exon 7 Nonsense KD c.928AT p.R310X 1 I This analysis
Missense KD c.932GA p.G311E 1 H This analysis
Exon 8 Missense KD c.1019TC p.L340P 1 H This analysis
Nonsense KD c.1189-1190delTG p.C347X 1 H This analysis
Missense KD c.1042GA p.V348E 1 H This analysis
Frameshift KD c.1095delC p.R365fsX8 1 H This analysis
Frameshift KD c.1099-1103delGGGGA p.E368fsX1 1 H This analysis
Deletion KD c.968-?_1129?del 1 H This analysisContinued on next page
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June 30, 2009:S32–42 Genetics and Genomics of PAHisease or associated with appetite suppressant intake
lter cysteine residues, and 2 residues altered in exon 5
ncode a receptor region of no known functional signif-
cance (13,20,47). Significantly, a recent in vitro study of
his mutation series has indicated that the signaling capacity
f receptors harboring atypical variation approaches physi-
logic levels (42). Akin to the cytoplasmic tail substitutions,
he relationship of these variants to the etiology of PAH is
ifficult to assess. A possible interpretation may be that
hese alleles produce PAH in the setting of additional
enetic or environmental risk factors.
are Disease Alleles Underlying PAH
HT is an autosomal dominant vascular disorder charac-
erized by the appearance of cutaneous telangiectasias and
rteriovenous malformations. The disease is caused by
athogenic mutations of either the TGF- type I receptor
ontinued
Table 1 Continued
Location
Mutation
Category Domain Nucleotide Change
Intron 8 Splice-site KD c.968-5AG
Exon 9 Missense KD c.1157AT
Missense KD c.1171GA
Nonsense KD c.1207CT
Frameshift KD c.1214delA
Nonsense KD c.1248-1251delATTT
Frameshift KD c.1271delTCCCAGinsCGGA
Intron 9 Splice-site KD c.12761GA
Splice-site KD c.1277-9AG
Exon 10 Nonsense KD c.1297CT
Frameshift KD c.1392delA
Exon 11 Missense KD c.1460AT
Missense KD c.1472GA
Exon 12 Missense CD c.1598AG
Frameshift CD c.2410-2413delGTCA
Frameshift CD c.2441-2442delAC
Frameshift CD c.2504insA
Frameshift CD c.2609del T
Nonsense CD c.2626CT
Nonsense CD c.2695CT
Nonsense CD c.2789CG
Exon 13 Missense CD c.2945AG
umbering is based on 1 of the initiation methionine.
ASD atrial-septal defect; CD cytoplasmic domain; ECD extracellular domain; F familial; I
eno-occlusive disease; TM  transmembrane; UTR  untranslated region.
NG Mutations Underlying PAH
Table 2 ENG Mutations Underlying PAH
Location Domain PAH Classification
Exon 5 ECD PAHHHT
Exon 10 ECD PAHHHT
Exon 11 ECD PAHHHTdexfenfluramine
Intron 12 ECD PAHHHTumbering is based on 1 of the initiation methionine of ALK1.
HHT  hereditary hemorrhagic telangiectasia; other abbreviations as in Table 1.LK-I or accessory receptor endoglin (ENG) (Table 2)
15,27,48,49), and, rarely, Smad 4, which is also associated
ith juvenile polyposis. A small proportion of HHT pa-
ients have PAH that is clinically and histopathologically
ndistinguishable from other heritable forms of PAH,
hereas others have PAH due to pulmonary arteriovenous
stulas (27). The underlying causative factor in these
atients is, typically, mutations of ALK-1. Up to 20% (16 of
3) of all detected mutations in ALK-1 are associated with
he development of PAH, and of these, 81% (13 of 16) are
onsistently observed with PAH (50,51). The majority of
hese defects comprise missense mutations and cluster in
unctional domains of the receptor, namely the kinase
omain and NANDOR box. In rare instances, mutations of
LK-1 (n  9) appear to cause IPAH or HPAH without
HT (Table 3) (27,38,48). Of interest, 4 mutations are
onfined to 2 discrete positions (amino acids 479 and 484)
Amino Acid Change
Frequency in
This Study Comment Reference
1 H This analysis
.E386V 1 H Fu et al. (39)
.A391T 1 I This analysis
.Q403X 1 H Fujiwara et al. (38)
.D405fsX6 1 H This analysis
.F417X 1 H This analysis
.F424fsX10 1 H This analysis
1 H This analysis
1 H This analysis
.Q433X 2 I,NK This analysis
.A465fsX9 1 H This analysis
.D487V 1 H This analysis
.R491Q 1 I This analysis
.H533R 1 I This analysis
.V804fsX1 1 H This analysis
.H814fsX2 1 H This analysis
.T835fsX6 1 PAHcollagen
disease
This analysis
.L870fsX1 1 I This analysis
.Q876X 1 H This analysis
.R899X 2 I This analysis
.S930X 2 I This analysis
.L982R 1 H This analysis
ic; KD kinase domain; NKnot known; PAH pulmonary arterial hypertension; PVOD pulmonary
leotide Change Amino Acid Change Reference
.682-686del p.S228fsX102 Harrison et al. (27)
.1334delT p.M445fsX44 Harrison et al. (27)
.del410G p.Q470fsX20 Chaouat et al. (15)
.1429-22TC Harrison et al. (48)
Mache et al. (49)p
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Genetics and Genomics of PAH June 30, 2009:S32–42f the kinase domain, suggesting that the native residues,
oth arginines, may be important for maintenance of the
ulmonary architecture (45). However, an important caveat
s that these patients usually present with early-onset disease
nd may go on to develop HHT at a later stage (38,48).
enetic Testing for PAH
linical genetic testing is available for PAH for BMPR2,
LK1, and ENG. In most cases, genetic analysis will
ommence with analysis of BMPR2 unless there are specific
linical symptoms or family history to suggest HHT, such as
ucocutaneous telangiectasias, recurrent epistaxis, gastroin-
estinal bleeding, or arteriovenous malformations in the
ulmonary, hepatic, gastrointestinal, or cerebral circula-
ions. Genetic testing may be offered to any individual with
family history of PAH or IPAH (without other known
ffected family members), and physicians may have a duty to
nform these patients of the possibility that PAH could
evelop in other family members. It may be necessary to go
ack to stored blood or DNA if the only affected family
ember is deceased and if those materials are available for
esting.
Evaluation of BMPR2 should begin with full sequencing
f all 13 exons, including splice junctions. If no mutation is
dentified by sequence analysis, further characterization for
enomic deletions and rearrangements should be evaluated
y an appropriate methodology, such as multiplex ligation-
ependent probe amplification. Using these combined ap-
roaches, approximately 70% of HPAH patients will have
dentified mutations in BMPR2 (36). Clinical genetic test-
ng is available in North America and Europe, with the
urrent cost of testing ranging from approximately U.S.
1,000 to $3,000 to analyze the first member of a family.
esting other family members for a family-specific mutation
s U.S. $300 to $500. Genetic testing should involve pre-test
nd post-test genetic counseling, ideally with a genetic
ounselor experienced in pulmonary hypertension. As a
onsequence of the incomplete penetrance and variable
ge of onset, identification of a BMPR2 mutation may
ave a complex and serious psychosocial impact on the
LK-1 Mutations Underlying PAH
Table 3 ALK-1 Mutations Underlying PAH
Location Domain PAH Classification Nucleotide Cha
Exon 2 ECD IPAH c.430CT
Exon 5 ECD IPAH c.536AC
Exon 7 KD HPAH c.936CG
Exon 8 KD IPAH c.1142TC
Exon 9 KD HPAH c.1270CA
Exon 10 KD IPAH c.1436GA
KD IPAH c.1436GC
KD IPAH c.1451GA
KD HPAH c.1451GA
umbering is based on 1 of the initiation methionine of ALK1.
IPAH  idiopathic pulmonary arterial hypertension; other abbreviations as in Tables 1 and 2.amily and is often associated with feelings of guilt in the tarent who has passed on mutation to the children.
enetic testing is most helpful when it is able to identify
embers of the family who are not genetically at risk for
AH, and who can then forgo serial evaluation for
etection of PAH.
The most common reasons that persons pursue genetic
esting are to inform their children of their hereditary
redisposition or to make informed decisions about family
lanning (52). In the past, many patients opted not to
ursue genetic testing because of anxiety regarding ge-
etic discrimination. Recognition of these concerns has
ed a number of countries to introduce either voluntary or
egal codes to protect individuals requesting genetic
ounseling and formal testing. For example, in the U.S.,
he Genetic Information Nondiscrimination Act, passed
n May 2008, protects members of both individual and
roup health insurance plans from discrimination in
overage or cost of health insurance coverage and also
rotects against discrimination in employment based
pon a genetic predisposition (53). Genetic testing of
hildren should be performed with caution, because of
he potentially significant psychological impact on a
hild, particularly overt anxiety for the future develop-
ent of a potentially fatal disease in the absence of
urrently known effective disease-prevention strategies.
linical Monitoring of Individuals at Risk
linical monitoring of patients with a family history of
AH or carriers of the BMPR2 mutation has not been
valuated rigorously. Consideration has been given to an-
ual clinical examination, echocardiogram, stress echocar-
iography, Doppler echocardiography during supine bicycle
xercise, and right heart catheterization at rest and with
xercise. The 1998 World Pulmonary Hypertension Con-
erence suggested that first-degree relatives of known
PAH patients should be screened annually using clinical
xamination and echocardiography. It is hoped that with
egular surveillance, individuals can be diagnosed earlier in
heir disease and benefit from early treatment. Although
Amino Acid Change Age at Onset Reference
p.R144X NK This analysis
p.D179A 51 yrs Harrison et al. (27)
p.H312Q 14 yrs Fujiwara et al. (38)
p.L381P 9 yrs Fujiwara et al. (38)
p.P424T 7 yrs Fujiwara et al. (38)
p.R479Q 7 yrs Fujiwara et al. (38)
p.R479P NK This analysis
p.R484Q 18 months Harrison et al. (27)
p.R484Q 2 yrs Fujiwara et al. (38)ngehere are currently no data to suggest that early diagnosis
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54,55).
eproductive Planning
renatal testing is available for BMPR2 mutations if a
amilial mutation has been identified. For a prospective
arent carrying a known BMPR2 mutation, there is a 50%
isk of transmitting this mutation to any offspring (56).
renatal testing can be performed by chorionic villus sam-
ling as early as the 10th week of pregnancy. However,
artly in consequence of the reduced penetrance of PAH
isease mutations, in our experience, very few families have
ursued this option. Additionally, pre-implantation genetic
iagnosis is available, whereby families use in vitro fertili-
ation, and genetic testing is performed on the embryo prior
o embryo transfer. Only embryos without the familial
MPR2 mutation are transferred to the uterus. This option
ay prove more appealing, particularly to women who are
arriers of the BMPR2 mutation and have been advised not
o pursue a pregnancy because of the increased risk of
eveloping PAH symptoms themselves. In such cases, in
itro fertilization is already required for surrogacy. However,
re-implantation genetic diagnosis with in vitro fertilization
s costly, may not be covered by insurance in the U.S., and
s not available in all European countries. Pre-implantation
enetic diagnosis has some associated diagnostic errors (57).
dentifying Novel, Highly
enetrant Genes for HPAH
small percentage of HPAH families have multiple af-
ected individuals but do not have identified mutations in
MPR2, despite full sequencing of exons and splice junc-
ions and testing for genomic alterations (9–12). Although
any of these families have limited numbers of living
ffected family members available for research, HPAH in
hese families may be due to locus or allelic heterogeneity
hat could be identified by sequencing of candidate genes, or
andidate Gene Association Studies Conducted in PAH
Table 4 Candidate Gene Association Studies Conducted in PAH
Gene PAH Classification Patient Sample (n) Control Sa
ACE Not specified 60 15
Not specified 51 20
Hypoxic 48 3
5-HTT PAHappetite suppressants 89 8
IPAH/CTEPH 74/35 Unkn
HPAH/IPAH/APAH 133/259/136 25
HPAH/IPAH 166/83 12
Endoglin PAHsystemic sclerosis 23 14
PGIS CTEPH 90 14
Kv1.5 IPAH NO responders
42
NO nonre
3
CE angiotensin converting enzyme; APAH associated pulmonary arterial hypertension; CTEPH
ypertension; HTT  hydroxy-tryptamine (serotonin) transporter; I  insertion; Kv1.5  potassium channe
ther abbreviations as in Tables 1 and 3.n rare cases, analyzed by linkage if sufficient numbers of
ffected family members are available. As our ability to
ost-effectively sequence and interpret greater amounts of
NA grows, we should be able to analyze the BMPR2
utation-negative HPAH cases for mutations in the whole
MPR2 genomic locus and for other physiologic candidate
enes.
enetic Modifiers of Risk for PAH
he complex clinical features of PAH, including variable
ge of disease onset both within and between families and
ex-dependent penetrance, imply the existence of additional
actors capable of modulating disease susceptibility (58).
oreover, the likely existence of environmental modifiers is
ighlighted by our observation of at least 7 pairs of
onozygotic twins discordant for disease (R. C. Trembath,
ersonal communication, September 2008). To date, a
umber of studies examining the contribution of variations
n candidate genes considered to play a biological role in the
tiology of PAH have been conducted (40,59–68). How-
ver, all the case/control analyses suffer from critically small
ample cohorts that would be unlikely to identify genetic
odifiers of moderate effect size. Further, validation
hrough independent replication studies, a crucial second
tage of association analyses, has been lacking in most of the
tudies performed to date (Table 4) (35,59–64,66–68).
enome-Wide Association (GWA) Analysis in IPAH
riven by the HapMap project (69) and the development of
enotyping platforms facilitating analysis of several hundred
housand independent loci, an understanding of the human
aplotypic architecture of sequence variation and the iden-
ification of loci conferring even modest risks for disease are
ow feasible. To achieve the power required to conduct a
WA study and to detect signals of modest genotypic
elative risk (GRR), large numbers of cases and controls and
(n)
Association
(Patient/Control Frequency)
Significance
(p Value) Reference
DD genotype (0.45/0.28) 0.01 Abraham et al. (59)
No association N/A Hoeper et al. (63)
I allele (0.67/0.38) 0.003 Aldashev et al. (60)
II genotype (0.65/0.27) 0.001 Eddahibi et al. (62)
No association N/A Koehler et al (64)
No association N/A Machado et al. (35)
II genotype with early onset
in FPAH
0.02 Willers et al. (67)
6bINS (0.11/0.24) 0.01 Wipff et al. (68)
No association N/A Amano et al. (61)
rs SNP4 a allele; SNP17 a allele
(0.07/0.23; 0.016/0.06)
0.01/0.05 Remillard et al. (66)
nic thromboembolic pulmonary hypertension; D deletion; HPAH heritable pulmonary arterialmple
8
0
0
4
own
3
5
0
4
sponde
7
 chro
l subunit 1.5; NO  nitric oxide; PGIS  prostacyclin synthase gene; PH pulmonary hypertension;
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70,71).
WA Study Design in IPAH
staged approach will be taken, using a common genotyp-
ng platform and concurrent screens. This will provide a
ataset of 1,000 cases and 3,000 controls. All patients
ill be screened for mutations in BMPR2 and ALK-1, and
utation carriers will be removed from the analysis. Data
rom the 2 screens may be combined in a meta-analysis (72).
ased on power calculation simulations, these numbers are
onsidered sufficient to detect variants of moderate effect
ize (GRR 1.3). The second stage of the study will be
ndependent replication by a GWA performed on a com-
ined cohort of North American IPAH cases and controls.
gain, the datasets will be combined in a meta-analysis, and
oci displaying significant association across the 3 studies
ill be chosen for further interrogation. In this way, the
alse-positive report rate is anticipated to be limited and the
ikelihood of true associations with IPAH increased (73).
Publicly available data from the HapMap consortium on
he extent of linkage disequilibrium in regions displaying
ositive signals will be used to fine-map associated loci and
stablish a panel of tagging single nucleotide polymor-
hisms. Where strong association is identified with low-
requency haplotypes, candidate genes will be resequenced
o capture rare, potentially causal variants. All potentially
unctional single nucleotide polymorphisms will subse-
uently be analyzed in all patient and control cohorts. A
ange of well-established statistical tools, including condi-
ional logistic regression, will be used to identify those
ariants most likely to be true susceptibility alleles.
odifiers of BMPR2
utation in Heritable Disease
he major PAH centers worldwide have access to at least
50 kindreds with identified BMPR2 mutations. Risk alleles
rom the IPAH GWA study will be assessed in affected
robands from these families by comparison to age- and
ex-matched unaffected mutation carriers to determine
hether, in the framework of BMPR2 mutation, they act as
odifiers in familial disease as well as IPAH.
uture Research
dentification of a substantial number of genetically at-risk
ndividuals offers the potential to develop an extremely
aluable resource for future studies, including assessment of
he natural history of PAH, development of biomarkers for
isease onset and progression, the identification of environ-
ental and genetic modifiers, and the opportunity to test
ethods for primary prevention. Biomarker development
ill benefit from advances in expression profiling, proteom-
cs, and metabolomics, by longitudinally testing individuals
t increased genetic risk. Interestingly, the largest number ofenetically at-risk individuals is within families of patients
urrently diagnosed with IPAH, given the relatively higher
revalence of this form of PAH. Through clinical genetic
esting programs or by enrollment in research programs,
uch kindreds will provide an invaluable resource for study-
ng PAH and potentially identifying preventive measures.
learly these types of ambitious studies will require large
umbers of patients as well as collaboration among multiple
enters around the world. However, such a cohort of asymp-
omatic BMPR2 mutation carriers is likely to provide one of
he most powerful resources for an in-depth understanding of
AH pathogenesis and prospects for prevention.
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